Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 6/17/11  and contains information from public web pages.

Dr. S.K. Wangnoo

Wrong Dr. S.K. Wangnoo?

Employment History

  • Senior Consultant Endocrinologist
    Apollo Hospital
  • Senior Consultant, Department ofEndocrinology
    Apollo Hospital
  • Senior Consultant Endocrinologist
    Indraprastha Apollo Hospital
  • Senior Consultant
    Apollo Centre for Obesity , Diabetes and Endocrinology
  • Senior Consultant Endocrinologist
    Indaprastha Apollo Hospital
  • Apollo Hospital
15 Total References
Web References
childhealthcongress's posterous - Filed under 'endcrinology', 17 June 2011 [cached]
Dr. S.K. Wangnoo
Sr. Consultant, Dept. ofEndocrinology,
Apollo Hospital, New Delhi
I have been prescribing rosiglitazone to ..., 26 Feb 2010 [cached]
I have been prescribing rosiglitazone to a select group of patient in my clinical practice and have been following them regularly, and they are doing well and are yet to report any untoward cardiovascular effects,? said Dr. S. K. Wangnoo, Senior Consultant Endocrinologist, Apollo Hospital, New Delhi.
Preventive measures can help diabetics avoid brain stroke, heart attacks, 15 Nov 2009 [cached]
"In India, five to 10 percent of the patients of diabetes suffer from brain stroke after the age of 60 years," said S.K. Wangnoo, senior consultant endocrinologist at the Indraprastha Apollo Hospital.
"Diabetes patients are having accelerated atherosclerosis (more cholesterol depositions in blood vessels) due to which patients are prone to develop brain stroke or heart attack two to four times more than non-diabetic patients," he added.
"Indians have the so-called 'thrifty ..., 12 Nov 2011 [cached]
"Indians have the so-called 'thrifty genotype'-our genes are tuned so as to take care of metabolic requirements in periods of limited food intake," says Dr S.K. Wangnoo, senior consultant at Apollo Centre for Obesity, Diabetes and Endocrinology in Delhi.
"An injectable molecule of the GLP-1 class, bydureon, is approved in Europe and awaiting approval in India," says Wangnoo.
"Three gliptins," says Wangnoo, "are approved for usage in India: sitagliptin, saxagliptin and vildagliptin. The newest gliptin, linagliptin, is awaiting approval in India. Saxaglyptin has proved effective in the treatment of type 2 diabetics with kidney problems (not end-stage renal disease). This molecule is marketed by Bristol-Myers Squibb as Onglyza. Studies presented at the EASD indicate that long-term treatment of type 2 diabetes with gliptins for two years appeared to maintain improvement in HbA1C levels, adds Wangnoo. "These are relatively safe, with low potential for hypoglycaemia," he says.
"The EndoBarrier is a liner that fits inside a section of the intestine," says Wangnoo.
EFFECTIVE youth Ministry, 8 June 2004 [cached]
16 S.K. Wangnoo, senior consultant endocrinologist at Delhi's Indaprastha Apollo Hospital
Other People with the name "Wangnoo":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.